Natera is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company’s screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants’ false and misleading claims about Natera’s technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.
If you incurred a loss on NTRA common stock purchased between February 26, 2020 and April 19, 2022, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Western District of Texas, and our firm is reaching out to investors to discuss their legal rights.
If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.
You only have until June 27, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.